证券代码：301075 证券简称：多瑞医药 公告编号：2026-【】 西藏多瑞医药股份有限公司 关于减持回购股份比例达到 1%的进展公告 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股 份》等相关规定，上市公司采用集中竞价交易方式减持回购股份期间， 减持回购股份占上市公司总股本的比例每达到 1%的，应当在事实发 生之日起 3 个交易日内予以披露。现将有关情况公告如下： 截至 2026 年 3 月 6 日，公司通过集中竞价交易方式累计减持回 购股份数量为 800,000 股，占公司总股本的 1.00%，减持所得资金总 额为 56,442,970.07 元，成交最高价为 86.88 元/股，成交最低价为 61.63 元/股，成交均价为 70.55 元/股。 三、风险提示 1、本次减持公司已回购股份计划实施存在不确定风险，公司将 根据市场情况、公司股价等具体情形决定实施对应股份减持计划，对 应减持计划存在减持时间、数量、价格的不确定性。 2、本次拟减持部分已回购股份事项符合《深圳证券交易所上市 公司自律监管指引第 9 号——回购股份》等相关规定。在上述减持期 | 本公司及董事会全体成员保证信息披露内容 ...

股票代码：301075 西藏多瑞医药股份有限公司 简式权益变动报告书 上市公司名称：西藏多瑞医药股份有限公司 股票上市地点：深圳证券交易所 股票简称：多瑞医药 信息披露义务人：西藏嘉康时代科技发展有限公司 住所/通讯地址：西藏自治区昌都市经济开发区 A 区生物医药园一号楼 1 楼 1006 号仓库 信息披露义务人之一致行动人：舟山清畅企业管理合伙企业（有限合伙） 住所/通讯地址：中国（浙江）自由贸易试验区舟山市定海区北蝉乡（综保区） 舟山港综合保税区企业服务中心 305-64503 室 权益变动性质：股份减少（要约收购，持股比例减少） 签署日期：2026 年 2 月 信息披露义务人声明 一、本报告书系根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》及相关的法律、法规和部门规章的有关规定编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其行为亦不违 反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2026-017 西藏多瑞医药股份有限公司 关于回购股份集中竞价减持的进展公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"）于 2025 年 12 月 19 日召开第二届董事会第二十五次会议，审议通过了《关于回购股 份集中竞价减持计划的议案》，同意公司根据《深圳证券交易所上市 公司自律监管指引第 9 号——回购股份》和公司于 2024 年 2 月 8 日 披露的《回购报告书》（公告编号：2024-012）的规定及要求，采用 集中竞价交易方式减持已回购股份，拟减持数量不超过 1,044,500 股， 占公司目前总股本比例为 1.31%；减持价格根据减持时的二级市场价 格确定；减持期间为自集中竞价减持计划公告披露之日起 15 个交易 日之后 6 个月内（即 2026 年 1 月 14 日至 2026 年 7 月 13 日，根据中 国证监会及深圳证券交易所相关规定禁止减持的期间除外）。具体内 容详见公司于 2025 年 12 月 19 ...

证券代码：301075 证券简称：多瑞医药 公告编号：2026-016 西藏多瑞医药股份有限公司 董事会 2026 年 2 月 27 日 关于王庆太、曹晓兵要约收购公司股份完成过户的公告 | 本公司及董事会全体成员保证信息披露内容的真实、准确和完 | | --- | | 整，没有虚假记载、误导性陈述或重大遗漏。 | 西藏多瑞医药股份有限公司（以下简称"公司"、"上市公司"或 "多瑞医药"）于 2026 年 1 月 21 日披露了《西藏多瑞医药股份有限 公司要约收购报告书》，王庆太、曹晓兵（以下简称"收购人"）向除 收购人及其一致行动人以外的公司全体股东发出部分要约，预定要约 收购股份数量为 19,440,000 股，占上市公司总股本的 24.30%，要约 收购价格为 32.07 元/股，要约收购期限为 2026 年 1 月 22 日至 2026 年 2 月 24 日。截至 2026 年 2 月 24 日，本次要约收购期限届满。根 据中国证券登记结算有限责任公司深圳分公司（以下简称"中登公司 深圳分公司"）提供的数据统计，本次要约收购期限内，王庆太预受 要约的股东账户总数为 3 户，预受要约股份总数为 17,6 ...

Group 1 - Duory Pharmaceutical (301075.SZ) experienced a 9.33% increase in stock price, reaching 70.080 yuan, marking a historical high for the company [1] - The total market capitalization of Duory Pharmaceutical is 5.606 billion yuan [1]

Core Viewpoint - The news highlights significant financial performance updates from various companies for the year 2025, showcasing both growth and recovery in net profits across multiple sectors, alongside notable corporate actions such as stock issuance and restructuring efforts. Performance Highlights - Huaming Equipment reported a net profit of 710 million yuan for 2025, a year-on-year increase of 15.54%, with a proposed cash dividend of 2.1 yuan per 10 shares [4] - Ziji Shenzhou achieved a net profit of 1.422 billion yuan for 2025, marking a turnaround from a previous loss [4] - Bingchuan Network posted a net profit of 479 million yuan for 2025, recovering from a loss of 247 million yuan in the previous year [5] - Zhenmao Technology's net profit surged by 582.01% to 133 million yuan [6] - Zhimingda's net profit increased by 466.74% to 110 million yuan [7] - Sanyou Medical reported a net profit of 63.29 million yuan, up 451.85% [8] - Baiaosaitu's net profit grew by 416.37% to 173 million yuan [9] - Green Harmony's net profit rose by 122.4% to 125 million yuan [10] - Juxin Technology's net profit increased by 91.95% to 205 million yuan [11] - Qiangyi Co. reported a net profit growth of 70.73% to 398 million yuan [12] - Nawei Technology's net profit increased by 64.18% to 136 million yuan [13] - Ailis reported a net profit of 2.181 billion yuan, up 52.55% [14] - Zhongchumei's net profit grew by 45.55% to 212 million yuan [15] Corporate Actions - Mingde Electronics plans to raise up to 1 billion yuan through a private placement for semiconductor projects and working capital [11] - Longpan Technology's private placement application was approved by the Shanghai Stock Exchange [11] - Guangxun Technology's private placement application was approved by the Shenzhen Stock Exchange [11] - Wangli Security decided to terminate its simplified procedure for issuing shares to specific investors for 2024 [11] - Debang Logistics applied to withdraw its stock from the Shanghai Stock Exchange and transition to the National SME Share Transfer System [12] - Dongfang Fortune's controlling shareholder plans to donate 20 million shares to Shanghai Jiao Tong University [12] - Duorui Pharmaceutical confirmed the results of a tender offer acquisition, with significant shareholding changes [12] Major Events - ST Huawen's restructuring application was accepted by the court, leading to a risk warning for its stock [3] - ST Jinglan's stock was suspended for trading due to significant price fluctuations unrelated to company performance [2] - Tianli Lithium Energy's subsidiary resumed production after completing maintenance [14] - ST Dali signed a procurement framework agreement with a leading new energy company, valued at approximately 888.79 million yuan [14]

Group 1 - Huang Yanming, the director of Dongfang Securities Research Institute, stated that the next investment focus in A-shares will be on mid-cap blue chips, moving away from the previous high-growth tech and high-dividend strategies [1] - The investment focus will be on three main areas: globally priced cyclical goods such as chemicals, non-ferrous metals, agricultural products, and global shipping; manufacturing sectors related to technology and national strength enhancement, including military industry, robotics, and new energy; and technology sectors related to large model performance realization [1] Group 2 - The International Institute of Finance reported that global debt has surged to a record $348 trillion, increasing by nearly $29 trillion, marking the fastest growth since the onset of the COVID-19 pandemic [2] - Government debt in countries like the United States and the Eurozone exceeds $10 trillion [2] Group 3 - Several lithium mining companies expect Zimbabwe's lithium ore exports to resume within one month after a temporary suspension [3] - Companies like Zhongmin Resources and Yahua Group are preparing to submit supplementary materials for export applications, indicating that the ban is expected to be lifted soon [3] Group 4 - Overseas tech companies are increasingly turning to loans backed by chips, particularly GPUs, to fund their substantial AI investments, with Moody's beginning to rate GPU-backed debt [4] - NAND flash memory prices are rising due to ongoing shortages, prompting major manufacturers like Phison to require advance payments from customers [4] Group 5 - The Chinese smartphone industry is set to experience a comprehensive price increase starting in March 2026, with new models expected to rise by at least 1,000 yuan [5] - Major brands such as OPPO, OnePlus, Vivo, iQOO, Xiaomi, and Honor are likely to raise prices for older models as well, marking a historic trend of simultaneous price hikes across all categories and brands [5] Group 6 - CCD cameras, once common, have seen a resurgence in popularity, with prices for certain models skyrocketing in the second-hand market [6] - Young consumers are driving this trend, primarily for the aesthetic quality of the images produced by these cameras [6] Group 7 - Baidu Group reported a total revenue of 32.7 billion yuan for Q4 2025, reflecting a year-on-year growth of 5% [7] - The net profit attributable to Baidu was 1.8 billion yuan, with a net profit margin of 5% [7] Group 8 - ByteDance's valuation is reportedly around $550 billion, as investment firm General Atlantic is selling part of its stake [8] - This valuation places ByteDance between Tencent and Alibaba in terms of market capitalization [8] Group 9 - New Hope Liuhe announced a cash investment of 74.87 million yuan to acquire a 70% stake in Luochuan Lingxian Company [9] - The investment will be used for both purchasing shares and increasing capital for the company [9] Group 10 - Aokema plans to acquire a 45% stake in its subsidiary Qingdao Aokema Smart Industry Co., Ltd. for 253 million yuan, aiming for full ownership [10] - The transaction is part of a strategy to consolidate control over its subsidiary [10]

Group 1 - Hehe Information achieved operating revenue of 1.81 billion yuan in 2025, a year-on-year increase of 25.83%, and net profit of 454 million yuan, a year-on-year increase of 13.39% [1] - Shengyi Technology announced that Guangxin Group and Chen Renxi have completed their share reduction plan, with Guangxin Group reducing its shares by 24.29 million, accounting for 1% of the total share capital [2] - Huaci Co., Ltd. received approval from the China Securities Regulatory Commission for its stock issuance to specific targets [3] Group 2 - New Nuo Wei plans to transfer 30.07% of its shares in Guoxin Huijin to Shiyao Holdings for 230 million yuan, with a valuation increase of 94.85% [4] - Tianli Lithium Energy has completed the scheduled maintenance of its lithium iron phosphate production line and resumed production [5] - Jinchuan Electric reported a net profit of 81.218 million yuan in 2025, a year-on-year decrease of 10.87% [6] Group 3 - Shenzhou Taiyue reported a net profit of 798 million yuan in 2025, a year-on-year decrease of 44.09% [7] - Jingwei Hengrun achieved a net profit of 99.5375 million yuan in 2025, reversing a loss from the previous year [8] - Keheng Technology signed a maximum pledge contract worth 450 million yuan to support its supply chain procurement [9] Group 4 - Zhongchu Media reported a net loss of 20.2858 million yuan in 2025, with operating revenue of 157 million yuan, a year-on-year decrease of 18.99% [10] - Tongde Chemical's subsidiary is involved in a lawsuit with a claim amount of approximately 49.1824 million yuan [12] - Jichuan Pharmaceutical signed an exclusive commercialization rights agreement for a new eczema treatment, with payments not exceeding 190 million yuan [13] Group 5 - Tianli Lithium Energy reported a net loss of 211 million yuan in 2025, with operating revenue of 408 million yuan, a year-on-year decrease of 20.20% [14] - Fortune Trend achieved a net profit of 315 million yuan in 2025, a year-on-year increase of 3.62% [15] - CITIC Securities received approval to publicly issue corporate bonds totaling no more than 80 billion yuan [16] Group 6 - Yongshan Lithium Industry reported a reduction of 23 million shares by Ningbo Jutai, decreasing its total shareholding from 13.24% to 4.52% [17] - Taifu Pump Industry achieved a net profit of 17.5631 million yuan in 2025, a year-on-year increase of 38.78% [18] - Longxun Co., Ltd. reported a net profit of 172 million yuan in 2025, a year-on-year increase of 19.05% [19] Group 7 - Duori Pharmaceutical's acquisition offer period has expired, and the company's stock will resume trading [20] - Tianhao Energy obtained a loan commitment letter for stock repurchase from a financial institution, with a loan amount not exceeding 90 million yuan [21] - Lijun Co., Ltd. reported a net profit of 57.545 million yuan in 2025, a year-on-year decrease of 52.09% [22] Group 8 - Zhongchumai reported a net profit of 212 million yuan in 2025, a year-on-year increase of 45.55% [23] - Kangxino reported a net profit of 27.8727 million yuan in 2025, reversing a loss from the previous year [24] - Baiao Saitu achieved a net profit of 173 million yuan in 2025, a year-on-year increase of 416.37% [25] Group 9 - Guangxun Technology's private placement application was approved by the Shenzhen Stock Exchange [26] - Sandam Membrane reported a net profit of 378 million yuan in 2025, a year-on-year increase of 19.95% [27] - Shangsheng Electronics reported a net profit of 184 million yuan in 2025, a year-on-year decrease of 21.71% [28] Group 10 - Xin'an Century reported a net profit of 79.2904 million yuan in 2025, reversing a loss from the previous year [29] - Zhenlei Technology achieved a net profit of 133 million yuan in 2025, a year-on-year increase of 582.01% [30] - Fuan Pharmaceutical's subsidiary received approval for a new drug application [32] Group 11 - Baotai reported a net loss of 336 million yuan in 2025, with operating revenue of 934 million yuan [33] - Aohua Endoscope reported a net profit of 11.4619 million yuan in 2025, a year-on-year decrease of 45.45% [34] - Maide Medical reported a net profit of 65.2599 million yuan in 2025, reversing a loss from the previous year [35] Group 12 - Chip Original Co. reported a net loss of 528 million yuan in 2025, with operating revenue of 3.152 billion yuan [36] - Zhongwei Semiconductor set a preliminary transfer price of 43.35 yuan per share for its inquiry [37] - Tieke Railway reported a net profit of 171 million yuan in 2025, a year-on-year decrease of 20.09% [38] Group 13 - Changjiang Electric announced a cash dividend distribution plan of 2.1 yuan per 10 shares for the 2025 fiscal year [39] - Kunheng Shunwei reported a net profit of 46.7676 million yuan in 2025, a year-on-year increase of 26.28% [40] - Ailis reported a net profit of 2.181 billion yuan in 2025, a year-on-year increase of 52.55% [41] Group 14 - Aerospace Software reported a net loss of 11.3126 million yuan in 2025, with operating revenue of 1.216 billion yuan [42] - Qizhong Technology reported a net profit of 266 million yuan in 2025, a year-on-year decrease of 15.16% [43] - Guotou Zhonglu plans to acquire 70% of Luochuan Lingxian Company for 74.8745 million yuan [44] Group 15 - Aokema plans to acquire 45% of its subsidiary for 253 million yuan [45] - ST Dali signed a procurement framework agreement worth 88.8794 million yuan with a leading new energy company [46] - Zhifei Biological received clinical trial approval for a new mRNA vaccine [47]

Core Viewpoint - The announcement details the completion of a tender offer by Duori Pharmaceutical, with significant share acquisition by key individuals, leading to a majority stake in the company [1] Group 1: Tender Offer Details - Duori Pharmaceutical disclosed the tender offer report on January 21, 2026 [1] - The tender offer period ended on February 24, 2026 [1] - Wang Qingtai accepted a total of 17,600,600 shares, while Cao Xiaobing accepted 1,851,400 shares during the tender offer [1] Group 2: Shareholding Impact - Following the completion of the tender offer, the acquirer and their concerted parties hold a total of 43,120,000 shares [1] - This represents 53.90% of the total share capital of the listed company [1] Group 3: Stock Resumption - The company has applied to the Shenzhen Stock Exchange for the resumption of its stock trading [1] - Trading is set to resume on February 27, 2026 [1]

Group 1 - The core point of the article is that Duori Pharmaceutical (301075.SZ) announced the completion of the acquisition offer by Wang Qingtai and Cao Xiaobing, with the acquirers and their concerted parties holding a total of 43.12 million shares, accounting for 53.90% of the total share capital [2] - The company's equity distribution still meets the listing conditions after the acquisition [2] - The company's stock will resume trading on February 27, 2026 [2]